Supernus Launches Oxtellar XR(TM) in the United States Read more about Supernus Launches Oxtellar XR(TM) in the United States
Supernus Appoints Victor Vaughn as Senior Vice President of Sales Read more about Supernus Appoints Victor Vaughn as Senior Vice President of Sales
Supernus Announces Pricing of Public Offering Read more about Supernus Announces Pricing of Public Offering
Supernus Announces Positive Phase IIb Results on SPN-810 and Decision to Advance to Late Stage Development Read more about Supernus Announces Positive Phase IIb Results on SPN-810 and Decision to Advance to Late Stage Development
Supernus Receives Three Years of Market Exclusivity for Oxtellar XR(TM) Read more about Supernus Receives Three Years of Market Exclusivity for Oxtellar XR(TM)
Supernus Pharmaceuticals Reports Third Quarter 2012 Financial Results Read more about Supernus Pharmaceuticals Reports Third Quarter 2012 Financial Results
Supernus Announces Issuance of Two Patents Covering Trokendi XR(TM) Read more about Supernus Announces Issuance of Two Patents Covering Trokendi XR(TM)
Supernus Announces Resignation of Board Member Read more about Supernus Announces Resignation of Board Member
Supernus Receives FDA Approval for Oxtellar XR(TM) in Epilepsy Read more about Supernus Receives FDA Approval for Oxtellar XR(TM) in Epilepsy
Supernus to Present at Two Investor Conferences in September 2012 Read more about Supernus to Present at Two Investor Conferences in September 2012